Company: BNBX
Filing Date: 2025-01-10
Form Type: S-1/A
Source: 0001104659-25-002521
Chunk: 10

Company: BNB PLUS CORP.
Filing Date: 2025-01-10
Form: S-1/A
Chunk 10
---
 related contracts will be entered into. In response to
this demand, the continued growth of the mRNA therapeutic market, and the unique abilities of the LineaDNA platform, the Company acquired
Spindle Biotech, Inc. (“Spindle”) in July 2023 to potentially increase its mRNA-related total addressable market (“TAM”)
to include the manufacture and sale of RNAP for use in conjunction with our LineaDNA IVT templates.

Through our acquisition of Spindle, we launched
our Linea IVT platform in July 2023, which combines Spindle’s proprietary high-performance RNAP, now marketed by the Company
as Linea RNAP, with our enzymatically produced LineaDNA IVT templates. We believe the Linea IVT platform enables our customers to make
better mRNA, faster. Based on data generated by the Company, we believe the integrated Linea IVT platform offers the following advantages
over conventional mRNA production to therapy developers and manufacturers:

| · | The prevention or reduction                                                                                                   
 of double stranded RNA (“dsRNA”) contamination resulting in higher target mRNA yields with the potential to reduce downstream 
 processing steps. dsRNA is a problematic immunogenic byproduct produced during conventional mRNA manufacture;                 |

<div align='center'>3</div>

| · | delivery of IVT templates                                               
 in as little as 14 days for milligram scale and 30 days for gram scale; |

| · | reduced mRNA manufacturing 
 complexities; and          |

| · | potentially enabling mRNA                                         
 manufactures to produce mRNA drug substance in less than 45 days. |

According to the Company’s internal
modeling, the ability to sell both LineaDNA IVT templates and Linea RNAP under the Linea IVT platform potentially increases the Company’s
mRNA-related TAM by approximately 3-5x as compared to selling LineaDNA IVT templates alone, while also providing a more competitive offering
to the mRNA manufacturing market. Currently, Linea RNAP is produced for the Company under an ISO 13485 quality system by Alphazyme, LLC
(“Alphazyme”) a third-party CDMO located in the United States, which the Company believes is sufficient for early-stage clinical
use of the enzyme. In conjunction with Alphazyme, the Company recently completed manufacturing process development work on its Linea
RNAP to increase the production scale of the enzyme and reduce unit costs.

Manufacturing Scale-up

The Company plans to offer several quality grades